2024 年至 2031 年全球动物抗生素和抗生素市场（按产品、动物类型、交付方式和地区划分）

2024 年至 2031 年动物抗菌与抗生素市场评估

随着健康动物数量的增加，对皮革和牲畜产品日益增长的消费需求正在满足。因此，对肉、奶、皮等动物产品的需求预计将为兽医抗菌和抗生素市场提供巨大的成长前景。除此之外，动物中多种疾病的流行也是刺激市场发展的另一个因素。兽医抗菌和抗生素市场预计在 2023 年的收入将超过 69.5 亿美元，并继续成长，到 2031 年将达到约 117.5 亿美元的估值。

随着世界人口的增长，对肉类、家禽、蛋类和乳製品等动物蛋白质来源的需求正在迅速增加。需求的激增使得透过家禽养殖来增加动物数量成为必然，从而导致传染病的盛行率高，对治疗和预防抗生素的需求增加。因此，预计 2024 年至 2031 年期间当前市场将以约 6.10% 的复合年增长率大幅增长。

兽医抗菌和抗生素市场定义/概述

动物用抗菌药物和抗生素药物是用于治疗牛、伴侣动物和家禽的预防和后预防阶段细菌性疾病的药物。透过减少食用动物的细菌感染，这种治疗有助于维持动物健康、预防疾病爆发并确保食品安全。它有多种形式，包括口服片剂、注射剂、外用溶液和饲料添加剂。政府当局控制其生产和商业化，以确保兽医的安全性、有效性和正确使用。

儘管抗生素具有有效益处，但由于对抗生素抗药性的担忧，大多数地区不鼓励使用抗生素，甚至经常禁止使用抗生素。然而，世界某些地区仍存在使用抗生素促进生长的现象。人们对抗生素抗药性的认识不断提高，促使人们更加负责任地使用抗生素，强调仅在兽医开立处方时使用抗生素、完成整个疗程并考虑其他预防措施。此外，世界各地正在製定旨在遏制动物过度使用和滥用抗菌药物的法规。这可能会影响市场动态并鼓励采取负责任的使用方式。

哪些因素推动了动物抗菌和抗生素市场的采用？

人口成长和收入水准提高增加了对动物性蛋白质（包括肉类、牛奶和蛋类）的需求。这促使对抗生素的需求增加，以预防和治疗细菌和人畜共通感染，确保牲畜和家禽的健康和高产量。

牲畜易受多种细菌感染，这些感染可能对其健康和生产力造成严重后果，因此必须进行集约化畜牧业。因此，畜牧业正致力于减少过度拥挤和其他环境压力，以最大限度地降低牲畜和家禽爆发疾病的风险。

此外，抗菌药物和抗生素的使用越来越多，以降低农场死亡率和经济损失，这为市场带来了新的机会。消费者监管机构和行业利益相关者对动物福利的认识不断提高，强调确保为食品生产而饲养的动物的健康和福利符合道德标准和监管要求。

同样，使用这些治疗方法来促进动物福利和生长对监管机构来说也是有问题的，这可能会鼓励製造商在尽量减少对人类健康影响的环境中使用这些治疗方法。温和的药物。此类监管支持预计将为兽医抗菌和抗生素市场提供新的成长途径。

此外，宠物拥有量的增加促使对动物健康的投资激增，支持使用抗生素治疗伴侣动物感染的潜在可能性。

哪些课题会影响动物抗菌和抗生素市场的成长？

人们越来越担心，由于过度使用和滥用动物抗生素，抗生素抗药性 (AMR) 的蔓延，这是细菌获得抗药性的结果，其结果是现有抗生素对这些抗药性菌株无效。它会消失。这对动物和人类的健康构成了重大威胁，因为治疗抗药性细菌既困难又昂贵。

在全球范围内，政府对处方兽药使用的不断变化的法规对全球公司构成了课题，并阻碍了某些地区的负责任使用实践。

预计廉价替代品的出现将增加其使用，并促使与老抗生素相关的抗药性问题的持续存在。

此外，农民、兽医和宠物主人对负责任地使用抗生素缺乏认识和教育，可能会进一步阻碍抗生素的采用。同样，对于动物健康而言，有效且易得的抗生素替代品数量有限也是一大课题。新型抗生素和疫苗、噬菌体等替代方案的研究和开发正在进行中，但广泛应用可能需要时间。

目录

第 1 章 全球动物抗菌与抗生素市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球动物抗菌与抗生素市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球动物抗生素及抗生素市场（依产品划分）

• 概述
• 四环素类抗生素
• 青霉素
• 磺胺类药物
• 大环内酯类
• 其他

6. 全球动物抗生素及以动物类型划分的抗生素市场

• 概述
• 伴侣动物
• 食用动物

7. 全球动物抗生素及抗生素市场依交付方式划分

• 概述
• 口服粉
• 注入
• 预混料

8. 全球动物抗生素及抗生素市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章。

• 概述
• 各公司的市场排名
• 主要发展策略

第十章 公司简介

• Zoetis
• Merck Animal Health
• Merial
• Elanco
• Bayer HealthCare
• Biogenesis Bago
• HUVEPHARMA
• Ceva Sante Animale
• Dechra Pharmaceuticals
• ECO Animal Health

第 11 章：公司简介 - 主要发展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 12 章附录

• 相关研究

Animal Antibacterial And Antibiotics Market Valuation - 2024-2031

Growing demand for leather and animal products for consumption is satisfactory with an increase in the population of healthy animals. Thus, the demand for animal products such as meat, milk, skin, and others is projected to offer immense growth prospects to the Animal Antibacterial And Antibiotics Market. In addition to this, the high prevalence of diseases among animals is another factor enabling the market. Animal Antibacterial And Antibiotics Market surpassed a revenue of USD 6.95 Billion in 2023 and continue growing to reach a valuation of aroundUSD 11.75 Billion by 2031.

The global population is growing, leading to an upsurge in demand for animal-derived protein sources like meat, poultry, eggs, and dairy products. This spurring demand necessitates an increase in animal populations through poultry practices, resulting in a higher prevalence of infections and a greater need for antibiotics for treatment and prevention. Thus, the current market is projected to grow substantially at aCAGR of approximately 6.10% from 2024 to 2031.

Animal Antibacterial And Antibiotics Market: Definition/ Overview

Animal antibacterial and antibiotics are treatments designed to treat bacterial illnesses, which are in the prophylaxis and metaphylaxis stage, in cattle, companion animals, and poultry. This form of treatment helps preserve animal health, prevent disease outbreaks, and ensure food safety by reducing bacterial infections in food-producing animals. It is present in a variety of forms, including oral pills, injectables, topical solutions, and feed additives. The government authorities control their manufacturing and commercialization to assure their safety, effectiveness, and correct usage in veterinary care.

Despite its effective benefits, it is discouraged and often banned in the majority of the regions due to concerns about antimicrobial resistance. However, the use of antibacterials for growth promotion still exists in some parts of the world. Growing awareness about antimicrobial resistance necessitates a shift towards responsible use practices, emphasizing only using antibiotics when prescribed by a veterinarian, completing the full course of treatment, and exploring alternative preventive measures. Also, evolving regulations worldwide aim to inhibit the overuse and misuse of antimicrobials in animals. This will likely influence market dynamics and encourage the adoption of responsible use practices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Animal Antibacterial And Antibiotics Market?

Growing population growth and income levels is bolstering the demand for animal protein, including meat, milk, and eggs. Therefore, there is a greater need to maintain the health and productivity of livestock and poultry to prevent and treat bacterial infections or zoonotic diseases using antibiotics.

As the animals are highly susceptible to various bacterial infections that can seriously affect their health and productivity, there is need for need for implementing intensive animal farming practices. Thus, the animal husbandry sector is majorly focusing on lowering overcrowding and other environmental stress to minimize risks of disease outbreaks in livestock and poultry.

Additionally, the use of antibacterial drugs and antibiotics is increasing to reduce mortality and economic losses of farmers, opening new doors of opportunities for the market. The rise in awareness among consumers regulators and industry stakeholders about animal welfare emphasizes ensuring the health and welfare of animals raised for food production so as to meet ethical standards and regulatory requirements.

Similarly, the use of these treatments for the well-being as well as promoting growth of the animals is concerning the regulatory bodies, thereby encouraging the manufacturers to develop eco-friendly drugs with minimal impact on human health. This regulatory support is anticipated to offer new avenues of growth to the Animal Antibacterial And Antibiotics Market.

Furthermore, increased pet ownership is surging investments in animal health, thereby boosting the potential potential use of antibiotics for treating infections in companion animals.

What are the Challenges Impacting the Growth of the Animal Antibacterial And Antibiotics Market?

Growing concerns regarding the spread of antimicrobial resistance (AMR) due to the overuse and misuse of antibiotics in animals is likely to result in bacteria developing resistance, thus, rendering existing antibiotics ineffective against these resistant strains. This poses a significant threat to animal and human health, as treating the resistant bacterial infections is difficult as well as expensive.

Changing government regulations globally against the use of prescribed veterinary drugs is creating challenges for global companies and hindering responsible use practices in some regions.

The availability of cheaper alternative drugs is projected to increase its usage, thereby contributing to the persistence of resistance issues associated with older antibiotics.

Moreover, inadequate awareness and education among farmers, veterinarians, and pet owners regarding responsible antibiotic use will further hinder its adoption. Similarly, the limited availability of effective and readily available alternatives to antibiotics for animal health poses a huge challenge. While research and development efforts are underway for novel antimicrobials and alternative solutions like vaccines and bacteriophages, their widespread adoption is likely to take time.

Category-Wise Acumens

Which Delivery Mode helps in the Growth of the Animal Antibacterial And Antibiotics Market?

Oral administration is anticipated to hold a major in the market over the forecast period. The easy availability at affordable prices and convenience in the usage of oral drugs is projected to help the segment retain its top-notch position in the Animal Antibacterial And Antibiotics Market.

In addition to this, the option of mass medication in food-producing animals further enhances its use through feed and water additives.

Consequently, the choice of catering to different animal preferences and ease of administration in oral formulations, including powders, tablets, premixes, and medicated feed additives, further boosts the demand for these treatments in animal husbandry.

Will the Effectiveness of Tetracyclines Help Skyrocket the Sales of Animal Antibacterial and Antibiotics?

As per our analyst, the tetracyclines segment is projected to hold the largest market share globally. This dominance is primarily due to their broad-spectrum effectiveness and affordability.

Also, their well-established application in veterinary practices is another driving factor despite its increasing and long-lasting impact on the development of bacterial resistance.

Another widely used segment is penicillin, particularly owing to its effectiveness against specific bacterial infections in food-producing animals. However, its dominance might also be affected owing to the changing resistance patterns and also the evolving regulatory restrictions.

Country/Region-wise Acumens

Which region has most potential for growth of Animal Antibacterial And Antibiotics Market?

According to VMR analyst, The Asia-Pacific region's fast-increasing population and rising disposable incomes are driving up demand for animal protein, such as meat, dairy, and eggs. As a result, there is an increasing need to protect the health and production of livestock and poultry by using antibacterial and antibiotics to prevent and cure bacterial diseases.

Economic development in Asia-Pacific countries has resulted in increased intensive agricultural techniques and upgrading of livestock and poultry production systems. This tendency has raised the need for veterinary medications, such as antibacterial and antibiotics, to treat the health risks linked with intensive animal agriculture. The Asia-Pacific area is vulnerable to a variety of infectious illnesses affecting cattle and poultry, such as respiratory diseases, gastrointestinal infections, and vector-borne diseases. Climate variability, urbanization, and globalization all contribute to the development of animal illnesses, resulting in a high need for antibacterial and antibiotics for disease prevention and treatment.

Many nations in the Asia-Pacific area are launching measures to improve animal health and welfare, raise food safety requirements, and promote sustainable agriculture methods. This includes expenditures in veterinary infrastructure, R&D, and regulatory frameworks to guarantee that antibacterial and antibiotics are used responsibly in animal husbandry.

Which Region Dominates in Animal Antibacterial And Antibiotics Market?

North America has a well-established veterinary health infrastructure, including veterinary clinics, hospitals, and diagnostic laboratories equipped with advanced diagnostic and treatment equipment. This infrastructure supports the diagnosis, treatment, and prevention of bacterial infections in animals, increasing demand for antibacterial and antibiotics. For instance,

the World Health Organization

reports that animal origins account for 70% of newly discovered human diseases. Therefore, Ceva has a responsibility to stop these zoonotic illnesses as a veterinarian company. To present, more than fifty vaccinations have been developed to protect against 19 major zoonoses. Furthermore, more than 50% of Ceva's product line consists of vaccinations and other treatments for animal care.

North America has a large and diverse livestock and poultry industry, including beef, dairy cows, swine, poultry, and aquaculture. Operations Intensive agricultural practices in this region create a significant demand for antibacterial agents and antibiotics to maintain the health and productivity of animals raised for food production. North American regulatory agencies such as the US Food and Drug Administration (FDA) and the Canadian Food Agency. (CFIA) has strict standards and regulations regarding the approval, distribution, and use of veterinary drugs, including antibacterial drugs and antibiotics. Compliance with the law ensures the safety, effectiveness, and quality of veterinary medicines in the region.

North American consumers are very aware and concerned about food safety, animal welfare and the use of antibiotics in livestock production. As a result, demand for animal products from animals raised without antibiotics is increasing, which encourages the adoption of alternative therapies and consumer preferences for veterinary medicines, enabling the region to hold a dominant position in the market.

Competitive Landscape

The competitive landscape in the Animal Antibacterial And Antibiotics Market is dynamic and evolving, driven by changing customer preferences and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the Animal Antibacterial And Antibiotics Market include:

Ashish Life Science, Merck Animal Health, Ayurvet, H. Boehringer Sohn AG & Co. KG., Ceva Sante Animale, Merial, Biogenesis Bago, Bayer HealthCare, Elanco, Endovac Animal Health., HIPRA, S.A., ECO Animal Health, HUVEPHARMA, Kyoritsuseiyaku Corporation, Dechra Pharmaceuticals, Neogen Corporation, Phibro Animal Health Corporation, UCBVET Animal Health and Welfare, Vetoquinol, Virbac, Zoetis.

Latest Developments

In February 2024, Elanco Animal Health Incorporated entered into an agreement to sell its aqua business to Merck Animal Health (NYSE:

MRK

) for around USD 1.3 Billion in cash, which is 7.4x the revenue of the Elanco aqua business estimated in 2023.

In July 2022, Boehringer Ingelheim, Evotec SE, and bioMerieux signed a joint venture agreement to develop the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

In May 2022, Ceva Sante Animale acquired Artemis Technologies, Inc., the Canadian oral rabies vaccine manufacturer. This acquisition will prove profitable as Ceva would be gaining control over the commercialization of ONRAB(R), a rabies glycoprotein recombinant oral vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Tetracyclines
• 5.3 Penicillins
• 5.4 Sulfonamides
• 5.5 Macrolides
• 5.6 Others

6 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY ANIMAL TYPE

• 6.1 Overview
• 6.2 Companion Animals
• 6.3 Food-Producing Animals

7 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY DELIVERY MODE

• 7.1 Overview
• 7.2 Oral Powder
• 7.3 Solutions Injections
• 7.4 Premix

8 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Zoetis
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck Animal Health
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merial
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Elanco
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bayer HealthCare
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Biogenesis Bago
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 HUVEPHARMA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ceva Sante Animale
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Dechra Pharmaceuticals
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 ECO Animal Health
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research